Completed PHASE2 INTERVENTIONAL 4-arm NCT01156844

Efficacy, Safety and Pharmacokinetics of Different Regimens of Indacaterol

A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group, Repeated-dose Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Three Different Dosing Regimens of Inhaled Indacaterol Maleate in Patients With Persistent Asthma

Sponsor: Novartis Pharmaceuticals

Conditions Persistent Asthma

Interventions Indacaterol Placebo to Indacaterol

Updated 6 times since 2017 Last updated: Jul 22, 2011 Started: Mar 31, 2010 Primary completion: Jul 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01156844, this PHASE2 trial focuses on Persistent Asthma and remains completed. Sponsored by Novartis Pharmaceuticals, it has been updated 6 times since 2010, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Mar 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Novartis Pharmaceuticals

Data source: Novartis

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Amman, Jordan , Anniston, United States , Berlin, United States , Clearwater, United States , Cypress, United States , Denver, United States , Fresno, United States , Groningen, Netherlands , Houston, United States , Irbid, Jordan and 18 more locations